Tech Company Financing Transactions
Emmaus Life Sciences Funding Round
Korea Bio Medical Science Institute participated in a $1.7 million funding round for Emmaus Life Sciences. The round closed on 1/27/2016.
Transaction Overview
Company Name
Announced On
1/27/2016
Transaction Type
Venture Equity
Amount
$1,700,000
Round
Undisclosed
Investors
Proceeds Purpose
The funds will be used to advance Emmaus' pharmaceutical grade L-glutamine treatment (PGLG), which is currently under clinical development having completed its Phase 3 trial for the management of sickle cell disease (SCD), and for general corporate purposes.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
21250 Hawthorne Blvd. 800
Torrance, CA 90503
USA
Torrance, CA 90503
USA
Phone
Website
Email Address
Overview
Emmaus Life Sciences, Inc. is conducting a clinical trial for L-glutamine for sickle cell disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Yutaka Niihara
Chief Operating Officer
Willis Lee
VP - Administration
Lan Tran
VP - Finance
Yasushi Nagasaki
VP - R & D
Charles Stark
Browse more venture capital transactions:
Prev: 1/27/2016: Sure venture capital transaction
Next: 1/27/2016: Wonolo venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs